| 2YZA | A:16-268 | CRYSTAL STRUCTURE OF KINASE DOMAIN OF HUMAN 5'-AMP-ACTIVATED PROTEIN KINASE ALPHA-2 SUBUNIT MUTANT (T172D) |
| 3MY0 | X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488; X:202-488 | CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN-193189 |
| 3MTF | B:208-495; B:208-495 | CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR |
| 3OOM | A:208-495 | CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[1,2-B]PYRIDAZINE INHIBITOR K00507 |
| 3Q4U | D:208-495; D:208-495; D:208-495; D:208-495 | CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN-193189 |
| 3MV5 | A:150-408 | CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES |
| 3MVH | A:150-408 | CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES |
| 3O96 | A:150-408 | CRYSTAL STRUCTURE OF HUMAN AKT1 WITH AN ALLOSTERIC INHIBITOR |
| 3OCB | B:150-408; B:150-408 | AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR |
| 3OW4 | B:150-408; B:150-408 | DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS |
| 3QKK | A:150-408 | SPIROCHROMANE AKT INHIBITORS |
| 3QKL | A:150-408 | SPIROCHROMANE AKT INHIBITORS |
| 3QKM | A:150-408 | SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS |
| 1MRV | A:152-409 | CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN |
| 1MRY | A:152-409 | CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN |
| 1O6K | A:152-409 | STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP |
| 1O6L | A:152-409 | CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE |
| 2JDO | A:152-409 | STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE |
| 2JDR | A:152-409 | STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A-443654 |
| 2UW9 | A:152-409 | STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO-PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE |
| 2X39 | A:152-409 | STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(2,3-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB |
| 2XH5 | A:152-409 | STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(2,3-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB |
| 3KRW | A:191-453 | HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK) |
| 3KRX | A:191-453 | HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL) |
| 3Q4T | B:192-479; B:192-479 | CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN |
| 2QLU | A:190-478 | CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN |
| 3O50 | B:133-383; B:133-383 | CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA |
| 3O51 | A:133-383 | CRYSTAL STRUCTURE OF ANTHRANILAMIDE 10 BOUND TO AURORAA |
| 3MDY | C:204-491; C:204-491 | CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN-193189 |
| 3MTL | A:165-446 | CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INDIRUBIN E804 |
| 1JST | C:4-286; C:4-286 | PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A |
| 1JSU | A:13-286 | P27(KIP1)/CYCLIN A/CDK2 COMPLEX |
| 1JSV | A:4-286 | THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE |
| 1JVP | P:4-286 | CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365 |
| 1KE6 | A:4-286 | CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE |
| 1KE7 | A:4-286 | CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE |
| 1KE8 | A:4-286 | CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE |
| 1KE9 | A:4-286 | CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE |
| 1OGU | C:4-286; C:4-286 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR |
| 1OI9 | C:4-286; C:4-286 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR |
| 1OIQ | A:4-286 | IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION |
| 1OIR | A:4-286 | IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION |
| 1OIT | A:4-286 | IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION |
| 1OIU | C:4-286; C:4-286 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR |
| 1OIY | C:4-286; C:4-286 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR |
| 1OKV | C:4-286; C:4-286 | CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2 |
| 1OKW | C:4-286; C:4-286 | CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2 |
| 1OL1 | C:4-286; C:4-286 | CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2 |
| 1P2A | A:4-286 | THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR |
| 1P5E | C:4-286; C:4-286 | THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE (TBS) |
| 1PF8 | A:4-286 | CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR |
| 1PKD | C:4-286; C:4-286 | THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A |
| 1PXJ | A:4-286 | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE |
| 1PXK | A:4-286 | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'-HYDROXYIMINOFORMAMIDE |
| 1PXL | A:4-286 | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE |
| 1PXM | A:4-286 | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL |
| 1PXN | A:4-286 | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL |
| 1PXO | A:4-286 | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO-PHENYL)-AMINE |
| 1PXP | A:4-286 | HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE |
| 1PYE | A:4-286 | CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR |
| 1QMZ | C:4-286; C:4-286 | PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX |
| 1R78 | A:4-286 | CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR |
| 1URC | C:4-286; C:4-286 | CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY |
| 1URW | A:4-286 | CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B]PYRIDAZINE |
| 1V1K | A:4-286 | CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR |
| 1VYW | C:4-286; C:4-286 | STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 |
| 1VYZ | A:4-286 | STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 |
| 1W0X | C:4-286 | CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE. |
| 1W8C | A:4-286 | CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H-PURIN-2-YLAMINE AND MONOMERIC CDK2 |
| 1W98 | A:4-286 | THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E |
| 1Y8Y | A:4-286 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1, 5-A]PYRIMIDINE INHIBITOR |
| 1Y91 | A:4-286 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1, 5-A]PYRIMIDINE INHIBITOR |
| 2JGZ | A:4-286 | CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B |
| 2R3F | A:4-286 | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
| 2R3G | A:4-286 | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
| 2R3H | A:4-286 | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
| 2R3I | A:4-286 | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
| 2R3J | A:4-286 | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
| 2R3K | A:4-286 | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
| 2R3L | A:4-286 | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
| 2R3M | A:4-286 | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
| 2R3N | A:4-286 | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
| 2R3O | A:4-286 | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
| 2R3P | A:4-286 | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
| 2R3Q | A:4-286 | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
| 2R3R | A:4-286 | CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR |
| 2UUE | C:4-286; C:4-286 | REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS |
| 2UZB | C:4-286; C:4-286 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
| 2UZD | C:4-286; C:4-286 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
| 2UZE | C:4-286; C:4-286 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
| 2UZL | C:4-286; C:4-286 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
| 2UZN | A:4-286 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
| 2UZO | A:4-286 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
| 2V0D | A:4-286 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
| 2V22 | C:4-286; C:4-286 | REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS |
| 2VTA | A:4-286 | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
| 2VTH | A:4-286 | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN |
| 2VTI | A:4-286 | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
| 2VTJ | A:4-286 | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
| 2VTL | A:4-286 | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
| 2VTM | A:4-286 | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
| 2VTN | A:4-286 | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
| 2VTO | A:4-286 | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
| 2VTP | A:4-286 | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
| 2VTQ | A:4-286 | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
| 2VTR | A:4-286 | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
| 2VTS | A:4-286 | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
| 2VTT | A:4-286 | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
| 2VU3 | A:4-286 | IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. |
| 2VV9 | A:4-286 | CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE |
| 2W05 | A:4-286 | STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, COMPOUND 5B |
| 2W06 | A:4-286 | STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, COMPOUND 5C |
| 2W17 | A:4-286 | CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE, COMPOUND (S)-8B |
| 2W1H | A:4-286 | FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283), A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY |
| 2WEV | C:4-286; C:4-286 | TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN |
| 2WFY | C:4-286; C:4-286 | TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN |
| 2WHB | C:4-286; C:4-286 | TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN |
| 2WIH | C:4-286; C:4-286 | STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125 |
| 2WIP | C:4-286; C:4-286 | STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-H] QUINAZOLINE-3-CARBOXYLIC ACID |
| 2WMA | C:4-286; C:4-286 | STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A |
| 2WMB | C:4-286; C:4-286 | STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A |
| 2WPA | C:4-286; C:4-286 | OPTIMISATION OF 6,6-DIMETHYL PYRROLO 3,4-C PYRAZOLES: IDENTIFICATION OF PHA-793887, A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING |
| 2WXV | C:4-286; C:4-286 | STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(4,3-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR |
| 2X1N | C:4-286; C:4-286 | TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN |
| 2XMY | A:4-286 | DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS |
| 2XNB | A:4-286 | DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS |
| 3LE6 | A:4-286 | THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR |
| 3LFN | A:4-286 | CRYSTAL STRUCTURE OF CDK2 WITH SAR57, AN AMINOINDAZOLE TYPE INHIBITOR |
| 3LFQ | A:4-286 | CRYSTAL STRUCTURE OF CDK2 WITH SAR60, AN AMINOINDAZOLE TYPE INHIBITOR |
| 3LFS | A:4-286 | CRYSTAL STRUCTURE OF CDK2 WITH SAR37, AN AMINOINDAZOLE TYPE INHIBITOR |
| 3MY5 | C:4-286; C:4-286 | CDK2/CYCLINA IN COMPLEX WITH DRB |
| 3NS9 | A:4-286 | CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194 |
| 3PJ8 | A:4-286 | STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[4,3-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE. |
| 3PXF | A:4-286 | CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE |
| 3PXQ | A:4-286 | CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE |
| 3PXY | A:4-286 | CDK2 IN COMPLEX WITH INHIBITOR JWS648 |
| 3PXZ | A:4-286 | CDK2 TERNARY COMPLEX WITH JWS648 AND ANS |
| 3PY1 | A:4-286 | CDK2 TERNARY COMPLEX WITH SU9516 AND ANS |
| 3QHR | C:4-286; C:4-286 | STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC |
| 3QHW | C:4-286; C:4-286 | STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC |
| 2W96 | B:6-295 | CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN |
| 2W99 | B:6-295 | CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN |
| 2W9F | B:6-295 | CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN |
| 2W9Z | B:6-295 | CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN |
| 1UNH | B:4-286; B:4-286 | STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE, ALOISINE AND INDIRUBIN. |
| 3O0G | B:6-286; B:6-286 | CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE |
| 1JOW | B:13-300 | CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN |
| 1XO2 | B:13-300 | CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR, FISETIN |
| 1UA2 | D:13-295; D:13-295; D:13-295; D:13-295 | CRYSTAL STRUCTURE OF HUMAN CDK7 |
| 3LQ5 | A:19-315 | STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8 |
| 3MI9 | A:19-315 | CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB |
| 3MIA | A:19-315 | CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB |
| 3MY1 | A:19-315 | STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB |
| 1NVR | A:9-265 | THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE |
| 1NVS | A:9-265 | THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078 |
| 1ZLT | A:9-265 | CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG |
| 1ZYS | A:9-265 | CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR |
| 2QHN | A:9-265 | CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1A |
| 2R0U | A:9-265 | CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54 |
| 2WMQ | A:9-265 | CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS |
| 2WMR | A:9-265 | CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS |
| 2WMS | A:9-265 | CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS |
| 2WMT | A:9-265 | CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS |
| 2WMU | A:9-265 | CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS |
| 2WMV | A:9-265 | CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS |
| 2WMW | A:9-265 | CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS |
| 2X8D | A:9-265 | DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION |
| 2X8E | A:9-265 | DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION |
| 2X8I | A:9-265 | DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION |
| 2XEZ | A:9-265 | CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS |
| 2XF0 | A:9-265 | CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS |
| 2YWP | A:9-265 | CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR |
| 3JVR | A:9-265 | CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE |
| 3JVS | A:9-265 | CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE |
| 3NLB | A:9-265 | NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH |
| 3OT3 | A:9-265 | X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN |
| 3OT8 | A:9-265 | X-RAY CRYSTAL STRUCTURE OF COMPOUND 17R BOUND TO HUMAN CHK1 KINASE DOMAIN |
| 3PA3 | A:9-265 | X-RAY CRYSTAL STRUCTURE OF COMPOUND 70 BOUND TO HUMAN CHK1 KINASE DOMAIN |
| 3PA4 | A:9-265 | X-RAY CRYSTAL STRUCTURE OF COMPOUND 2A BOUND TO HUMAN CHK1 KINASE DOMAIN |
| 3PA5 | A:9-265 | X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN |
| 2W0J | A:220-486 | CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH NSC 109555, A SPECIFIC INHIBITOR |
| 2WTC | A:220-486 | CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR |
| 2WTI | A:220-486 | CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR |
| 2WTJ | A:220-486 | CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR |
| 2XBJ | A:220-486 | CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR |
| 2XM8 | A:220-486 | CO-CRYSTAL STRUCTURE OF A SMALL MOLECULE INHIBITOR BOUND TO THE KINASE DOMAIN OF CHK2 |
| 2XM9 | A:220-486 | STRUCTURE OF A SMALL MOLECULE INHIBITOR WITH THE KINASE DOMAIN OF CHK2 |
| 1Z57 | A:161-477 | CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH 10Z-HYMENIALDISINE |
| 2VAG | A:161-477 | CRYSTAL STRUCTURE OF DI-PHOSPHORYLATED HUMAN CLK1 IN COMPLEX WITH A NOVEL SUBSTITUTED INDOLE INHIBITOR |
| 3NR9 | C:163-479; C:163-479; C:163-479 | STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2) |
| 2WU6 | A:156-472 | CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH DKI |
| 2WU7 | A:156-472 | CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH V25 |
| 3RAW | B:156-472; B:156-472 | CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41 |
| 1JWH | B:39-324; B:39-324 | CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME |
| 1NA7 | A:39-324 | CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 |
| 1PJK | A:39-324 | CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT |
| 2PVR | A:39-324 | CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C-TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS |
| 2ZJW | A:39-324 | CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID |
| 3JUH | B:39-324; B:39-324 | CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY |
| 3MB6 | A:39-324 | HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA) |
| 3MB7 | A:39-324 | HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR) |
| 3NGA | B:39-324; B:39-324 | HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945 |
| 3NSZ | A:39-324 | HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN |
| 3RPS | B:39-324; B:39-324 | STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4,5,6,7-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL |
| 3OFM | A:40-325 | STRUCTURE OF A HUMAN CK2ALPHA PRIME, THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS |
| 3MFR | A:12-276 | CASK-4M CAM KINASE DOMAIN, NATIVE |
| 3MFS | A:12-276 | CASK-4M CAM KINASE DOMAIN, AMPPNP |
| 3MFT | A:12-276 | CASK-4M CAM KINASE DOMAIN, MN2+ |
| 3MFU | A:12-276 | CASK-4M CAM KINASE DOMAIN, AMPPNP-MN2+ |
| 1JKK | A:13-275 | 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG. |
| 1JKL | A:13-275 | 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE |
| 1JKS | A:13-275 | 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE |
| 1JKT | B:13-275; B:13-275 | TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE |
| 1P4F | A:13-275 | DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT |
| 1WVW | A:13-275 | CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS |
| 1WVX | A:13-275 | CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS |
| 2W4J | A:13-275 | X-RAY STRUCTURE OF A DAP-KINASE 2-277 |
| 2W4K | A:13-275 | X-RAY STRUCTURE OF A DAP-KINASE 2-302 |
| 2X0G | A:13-275 | X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX |
| 2YAK | A:13-275 | STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV) |
| 1WMK | H:13-275; H:13-275; H:13-275; H:13-275; H:13-275; H:13-275; H:13-275; H:13-275 | HUMAN DEATH-ASSOCIATED KINASE DRP-1, MUTANT S308D D40 |
| 1Z9X | C:13-275; C:13-275; C:13-275 | HUMAN DRP-1 KINASE, W305S S308A D40 MUTANT, CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT |
| 1ZWS | H:13-275; H:13-275; H:13-275; H:13-275; H:13-275; H:13-275; H:13-275; H:13-275 | CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE |
| 1YRP | B:13-275; B:13-275 | CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265 |
| 2VD5 | B:81-349; B:81-349 | STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII |
| 2VX3 | D:159-479; D:159-479; D:159-479; D:159-479 | CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A |
| 2WO6 | B:159-479; B:159-479 | HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE |
| 3KVW | A:149-462 | CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2) IN COMPLEX WITH AN INDIRUBIN LIGAND |
| 3NYN | B:186-448; B:186-448 | CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN |
| 3NYO | B:186-448; B:186-448 | CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP |
| 1O9U | A:56-340 | GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE |
| 1PYX | B:56-340; B:56-340 | GSK-3 BETA COMPLEXED WITH AMP-PNP |
| 1Q3W | B:56-340; B:56-340 | GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE |
| 1Q41 | B:56-340; B:56-340 | GSK-3 BETA COMPLEXED WITH INDIRUBIN-3'-MONOXIME |
| 1Q4L | B:56-340; B:56-340 | GSK-3 BETA COMPLEXED WITH INHIBITOR I-5 |
| 1Q5K | B:56-340; B:56-340 | CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR |
| 1R0E | B:56-340; B:56-340 | GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4-ARYLMALEIMIDE INHIBITOR |
| 1UV5 | A:56-340 | GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3'-OXIME |
| 2JLD | B:56-340; B:56-340 | EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3 |
| 2O5K | A:56-340 | CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR |
| 2OW3 | B:56-340; B:56-340 | GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS-(INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR |
| 3L1S | B:56-340; B:56-340 | 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3 |
| 3PUP | B:56-340; B:56-340 | STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1) |
| 3Q3B | B:56-340; B:56-340 | 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS |
| 3ZRK | B:56-340; B:56-340 | IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS |
| 3ZRL | B:56-340; B:56-340 | IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS |
| 3ZRM | B:56-340; B:56-340 | IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS |
| 2VUW | A:484-698 | STRUCTURE OF HUMAN HASPIN KINASE DOMAIN |
| 2NRU | D:187-455; D:187-455; D:187-455; D:187-455 | CRYSTAL STRUCTURE OF IRAK-4 |
| 2NRY | D:187-455; D:187-455; D:187-455; D:187-455 | CRYSTAL STRUCTURE OF IRAK-4 |
| 2O8Y | B:189-455; B:189-455 | APO IRAK4 KINASE DOMAIN |
| 2OIB | D:187-455; D:187-455; D:187-455; D:187-455 | CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM |
| 2OIC | D:187-455; D:187-455; D:187-455; D:187-455 | CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE |
| 2OID | D:187-455; D:187-455; D:187-455; D:187-455 | CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP |
| 3L9L | B:43-297; B:43-297 | CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36 |
| 3L9M | B:43-297; B:43-297 | CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A, L173M, Q181K) WITH COMPOUND 18 |
| 3L9N | A:43-297 | CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A, L173M, Q181K) WITH COMPOUND 27 |
| 3MVJ | E:43-297; E:43-297; E:43-297 | HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX |
| 2JC6 | C:23-279; C:23-279 | CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D |
| 2VZ6 | B:13-271; B:13-271 | STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804 |
| 2VN9 | B:14-272; B:14-272 | CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1, CAMKD |
| 2WEL | A:14-272 | CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN |
| 2V7O | A:14-272 | CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA |
| 2W4O | A:46-300 | CRYSTAL STRUCTURE OF HUMAN CAMK4 IN COMPLEX WITH 4-AMINO( SULFAMOYL-PHENYLAMINO)-TRIAZOLE-CARBOTHIOIC ACID (2,6-DIFLUORO-PHENYL)-AMIDE) |
| 2ZV2 | A:166-447 | CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2, BETA, CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609 |
| 1XJD | A:380-634 | CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION |
| 2JED | B:380-634; B:380-634 | THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION. |
| 2WNT | B:418-675; B:418-675 | CRYSTAL STRUCTURE OF THE HUMAN RIBOSOMAL PROTEIN S6 KINASE |
| 2Z7Q | A:62-321 | CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK-1 BOUND TO AMP-PCP |
| 2Z7R | A:62-321 | CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE |
| 2Z7S | A:62-321 | CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A |
| 1VZO | A:49-318 | THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN |
| 3KN5 | B:427-687; B:427-687 | CRYSTAL STRUCTURE OF THE C-TERMINAL KINASE DOMAIN OF MSK1 IN COMPLEX WITH AMP-PNP |
| 3KN6 | B:427-687; B:427-687 | CRYSTAL STRUCTURE OF THE C-TERMINAL KINASE DOMAIN OF MSK1 |
| 1KWP | B:64-325; B:64-325 | CRYSTAL STRUCTURE OF MAPKAP2 |
| 1NXK | D:64-325; D:64-325; D:64-325; D:64-325 | CRYSTAL STRUCTURE OF STAUROSPORINE BOUND TO MAP KAP KINASE 2 |
| 1NY3 | A:64-325 | CRYSTAL STRUCTURE OF ADP BOUND TO MAP KAP KINASE 2 |
| 2JBO | A:64-325 | PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-1, SOAKING) |
| 2ONL | D:78-325; D:78-325; B:24-308; B:24-308 | CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER |
| 2OZA | A:64-325 | STRUCTURE OF P38ALPHA COMPLEX |
| 2P3G | X:64-325 | CRYSTAL STRUCTURE OF A PYRROLOPYRIDINE INHIBITOR BOUND TO MAPKAP KINASE-2 |
| 3KA0 | A:64-325 | MK2 COMPLEX WITH INHIBITOR 6-(5-(2-AMINOPYRIMIDIN-4-YLAMINO)-2-HYDROXYPHENYL)-N-METHYLBENZO[B]THIOPHENE-2-CARBOXAMIDE |
| 3KC3 | L:64-325; L:64-325; L:64-325; L:64-325; L:64-325; L:64-325; L:64-325; L:64-325; L:64-325; L:64-325; L:64-325; L:64-325 | MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-2,4-DIAMINE |
| 3KGA | A:64-325 | CRYSTAL STRUCTURE OF MAPKAP KINASE 2 (MK2) COMPLEXED WITH A POTENT 3-AMINOPYRAZOLE ATP SITE INHIBITOR |
| 3M2W | A:64-325 | CRYSTAL STRUCTURE OF MAPKAK KINASE 2 (MK2) COMPLEXED WITH A SPIROAZETIDINE-TETRACYCLIC ATP SITE INHIBITOR |
| 3M42 | A:64-325 | CRYSTAL STRUCTURE OF MAPKAP KINASE 2 (MK2) COMPLEXED WITH A TETRACYCLIC ATP SITE INHIBITOR |
| 3R2B | L:64-325; L:64-325; L:64-325; L:64-325; L:64-325; L:64-325; L:64-325; L:64-325; L:64-325; L:64-325; L:64-325; L:64-325 | MK2 KINASE BOUND TO COMPOUND 5B |
| 3R2Y | A:64-325 | MK2 KINASE BOUND TO COMPOUND 1 |
| 3R30 | A:64-325 | MK2 KINASE BOUND TO COMPOUND 2 |
| 3R1N | A:44-304 | MK3 KINASE BOUND TO COMPOUND 5B |
| 2QNJ | B:56-330; B:56-330 | KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1 |
| 1PME | A:25-313 | STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE |
| 1TVO | A:25-313 | THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR |
| 1WZY | A:25-313 | CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE |
| 2OJG | A:23-311 | CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE |
| 2OJI | A:23-311 | CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE |
| 2OJJ | A:23-311 | CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE |
| 2ZOQ | B:42-330; B:42-330 | STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1 |
| 1UKH | A:26-321 | STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125 |
| 1UKI | A:26-321 | STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125 |
| 2NO3 | B:26-321; B:26-321 | NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS |
| 3O17 | B:26-321; B:26-321 | CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM |
| 3O2M | B:26-321; B:26-321 | CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118) |
| 3NPC | B:26-321; B:26-321 | CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796 |
| 1JNK | A:64-359 | THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP |
| 1PMN | A:64-359 | CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR |
| 1PMU | A:64-359 | THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR |
| 1PMV | A:64-359 | THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR |
| 2O0U | A:64-359 | CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1-PIPERIDINYL)PROPANOYL]-4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDIN-2-YL}-1-NAPHTHALENECARBOXAMIDE |
| 2O2U | A:64-359 | CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-CYANO-4,5,6,7-TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE |
| 2OK1 | A:64-359 | CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE |
| 2P33 | A:64-359 | SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N-TERMINAL KINASE (JNK) INHIBITORS |
| 2R9S | B:64-359; B:64-359 | C-JUN N-TERMINAL KINASE 3 WITH 3,5-DISUBSTITUTED QUINOLINE INHIBITOR |
| 2WAJ | A:64-359 | CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-3,4-DIHYDROISOQUINOLINE INHIBITOR |
| 2ZDT | A:64-359 | CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR |
| 2ZDU | A:64-359 | CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR |
| 3KVX | A:64-359 | JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR, SR-3562 |
| 3OXI | A:64-359 | DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| 3PTG | A:64-359 | DESIGN AND SYNTHESIS OF A NOVEL, ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR |
| 1KV2 | A:24-308 | HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB 796 |
| 1M7Q | A:24-308 | CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR |
| 1OUK | A:24-308 | THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR |
| 1OUY | A:24-308 | THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO-PYRIMIDINE INHIBITOR |
| 1OVE | A:24-308 | THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE |
| 1OZ1 | A:24-308 | P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR |
| 1R39 | A:24-308 | THE STRUCTURE OF P38ALPHA |
| 1R3C | A:24-308 | THE STRUCTURE OF P38ALPHA C162S MUTANT |
| 1W7H | A:24-308 | P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR |
| 1W82 | A:24-308 | P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR |
| 1W83 | A:24-308 | P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR |
| 1W84 | A:24-308 | P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR |
| 1WBN | A:24-308 | FRAGMENT BASED P38 INHIBITORS |
| 1WBO | A:24-308 | FRAGMENT BASED P38 INHIBITORS |
| 1WBS | A:24-308 | IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION. |
| 1WBT | A:24-308 | IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION. |
| 1WBV | A:24-308 | IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION. |
| 1WBW | A:24-308 | IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION. |
| 1WFC | A:24-308 | STRUCTURE OF APO, UNPHOSPHORYLATED, P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN |
| 1YQJ | A:24-308 | CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR |
| 1ZYJ | A:24-308 | HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A |
| 1ZZ2 | A:24-308 | TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES |
| 1ZZL | A:24-308 | CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE |
| 2NPQ | A:24-308 | A NOVEL LIPID BINDING SITE IN THE P38 ALPHA MAP KINASE |
| 2OKR | D:24-308; D:24-308 | CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER |
| 2QD9 | A:24-308 | P38 ALPHA MAP KINASE INHIBITOR BASED ON HETEROBICYCLIC SCAFFOLDS |
| 2RG5 | A:24-308 | PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B |
| 2RG6 | A:24-308 | PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J |
| 2ZAZ | A:24-308 | CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR |
| 2ZB0 | A:24-308 | CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR |
| 2ZB1 | A:24-308 | CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR |
| 3K3I | A:24-308 | P38ALPHA BOUND TO NOVEL DGF-OUT COMPOUND PF-00215955 |
| 3K3J | A:24-308 | P38ALPHA BOUND TO NOVEL DFG-OUT COMPOUND PF-00416121 |
| 3KF7 | A:24-308 | CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND |
| 3KQ7 | A:24-308 | STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1-METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]-2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE |
| 3L8S | A:24-308 | HUMAN P38 MAP KINASE IN COMPLEX WITH CP-547632 |
| 3L8X | A:24-308 | P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-PYRIMIDINE BASED INHIBITOR |
| 3LFA | A:24-308 | HUMAN P38 MAP KINASE IN COMPLEX WITH DASATINIB |
| 3LFB | A:24-308 | HUMAN P38 MAP KINASE IN COMPLEX WITH RL98 |
| 3LFC | A:24-308 | HUMAN P38 MAP KINASE IN COMPLEX WITH RL99 |
| 3LFD | A:24-308 | HUMAN P38 MAP KINASE IN COMPLEX WITH RL113 |
| 3LFE | A:24-308 | HUMAN P38 MAP KINASE IN COMPLEX WITH RL116 |
| 3LFF | A:24-308 | HUMAN P38 MAP KINASE IN COMPLEX WITH RL166 |
| 3LHJ | A:24-308 | CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR. |
| 3MGY | A:24-308 | MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE |
| 3MH0 | A:24-308 | MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE |
| 3MH3 | A:24-308 | MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE |
| 3MPA | A:24-308 | CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING |
| 3MPT | A:24-308 | CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2-CARBOXAMIDE INHIBITOR |
| 3MVL | B:24-308; B:24-308 | P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K |
| 3MVM | B:24-308; B:24-308 | P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V |
| 3MW1 | A:24-308 | P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR |
| 3NEW | A:24-308 | P38-ALPHA COMPLEXED WITH COMPOUND 10 |
| 3NNU | A:24-308 | CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376 |
| 3NNV | A:24-308 | CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437 |
| 3NNW | A:24-308 | CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802 |
| 3NNX | A:24-308 | CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802 |
| 3NWW | A:24-308 | P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR |
| 3O8P | A:24-308 | CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING |
| 3O8T | A:24-308 | CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING |
| 3O8U | A:24-308 | CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING |
| 3OC1 | A:24-308 | CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING |
| 3OCG | A:24-308 | P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR |
| 3OD6 | X:24-308 | CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT |
| 3ODY | X:24-308 | CRYSTAL STRUCTURE OF P38ALPHA Y323Q ACTIVE MUTANT |
| 3ODZ | X:24-308 | CRYSTAL STRUCTURE OF P38ALPHA Y323R ACTIVE MUTANT |
| 3OEF | X:24-308 | CRYSTAL STRUCTURE OF Y323F INACTIVE MUTANT OF P38ALPHA MAP KINASE |
| 3ROC | A:24-308 | CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND |
| 1S9J | A:68-361 | X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP |
| 2P55 | A:68-361 | X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP |
| 3MBL | A:68-361 | CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP |
| 3ORN | A:68-361 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH CH4987655 AND MGAMP-PNP |
| 3PP1 | A:68-361 | CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP |
| 1S9I | B:72-369; B:72-369 | X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP |
| 2X4F | B:106-361; B:106-361 | THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156. |
| 2W5A | A:8-271 | HUMAN NEK2 KINASE ADP-BOUND |
| 2W5B | A:8-271 | HUMAN NEK2 KINASE ATPGAMMAS-BOUND |
| 2WQO | A:8-271 | STRUCTURE OF NEK2 BOUND TO THE AMINOPYRIDINE CCT241950 |
| 2XK3 | A:8-271 | STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 35 |
| 2XK4 | A:8-271 | STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 17 |
| 2XK6 | A:8-271 | STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 36 |
| 2XK7 | A:8-271 | STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 23 |
| 2XK8 | A:8-271 | STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 15 |
| 2XKC | A:8-271 | STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 14 |
| 2XKD | A:8-271 | STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 12 |
| 2XKE | A:8-271 | STRUCTURE OF NEK2 BOUND TO AMINIPYRAZINE COMPOUND 5 |
| 2XKF | A:8-271 | STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 2 |
| 2XNM | A:8-271 | STRUCTURE OF NEK2 BOUND TO CCT |
| 2XNN | A:8-271 | STRUCTURE OF NEK2 BOUND TO CCT242430 |
| 2XNO | A:8-271 | STRUCTURE OF NEK2 BOUND TO CCT243779 |
| 2XNP | A:8-271 | STRUCTURE OF NEK2 BOUND TO CCT244858 |
| 2WQM | A:34-292 | STRUCTURE OF APO HUMAN NEK7 |
| 2WQN | A:34-292 | STRUCTURE OF ADP-BOUND HUMAN NEK7 |
| 2VWI | D:17-291; D:17-291; D:17-291; D:17-291 | STRUCTURE OF THE OSR1 KINASE, A HYPERTENSION DRUG TARGET |
| 1YHV | A:270-521 | CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R, T423E) |
| 1YHW | A:270-521 | CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R) |
| 2Q0N | A:322-572 | STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE |
| 2X4Z | A:322-572 | CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309 |
| 1OKY | A:82-341 | STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE |
| 1OKZ | A:82-341 | STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01 |
| 1UU3 | A:82-341 | STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531 |
| 1UU7 | A:82-341 | STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2 |
| 1UU8 | A:82-341 | STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1 |
| 1UU9 | A:82-341 | STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3 |
| 1UVR | A:82-341 | STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8 |
| 1Z5M | A:82-341 | CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-2,2-DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1 |
| 2PE0 | A:82-341 | CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-1,3-DIHYDRO-INDOL-2-ONE COMPLEX |
| 2PE1 | A:82-341 | CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-2,3-DIHYDRO-1H-INDOL-5-YL}-UREA {BX-517} COMPLEX |
| 2PE2 | A:82-341 | CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-1,2-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H-PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX |
| 2XCK | A:82-341 | CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR |
| 3NAX | A:82-341 | PDK1 IN COMPLEX WITH INHIBITOR MP7 |
| 3NAY | B:82-341; B:82-341 | PDK1 IN COMPLEX WITH INHIBITOR MP6 |
| 3ORX | H:82-341; H:82-341; H:82-341; H:82-341; H:82-341; H:82-341; H:82-341; H:82-341 | PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8 |
| 3ORZ | D:82-341; D:82-341; D:82-341; D:82-341 | PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2 |
| 3OTU | A:82-341 | PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30 |
| 3PWY | A:82-341 | CRYSTAL STRUCTURE OF AN EXTENDER (SPD28345)-MODIFIED HUMAN PDK1 COMPLEX 2 |
| 3QC4 | B:82-341; B:82-341 | PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX |
| 3QCQ | A:82-341 | PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3-AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-2,4-PYRIMIDINEDIAMINE |
| 3QCS | A:82-341 | PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2-AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE |
| 3QCX | A:82-341 | PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2-AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3-AMINE |
| 3QCY | A:82-341 | PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2-MORPHOLINECARBOXAMIDE |
| 3QD0 | A:82-341 | PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R,5S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N-PHENYL-3-PIPERIDINECARBOXAMIDE |
| 3QD3 | A:82-341 | PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 1,1-DIMETHYLETHYL {(3R,6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE |
| 3QD4 | A:82-341 | PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 1,1-DIMETHYLETHYL{(3R,5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE |
| 3RCJ | A:82-341 | RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE |
| 2Y7J | D:24-291; D:24-291; D:24-291; D:24-291 | STRUCTURE OF HUMAN PHOSPHORYLASE KINASE, GAMMA 2 |
| 1XQZ | A:38-290 | CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION |
| 1XR1 | A:38-290 | CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION |
| 1XWS | A:38-290 | CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN |
| 1YHS | A:38-290 | CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE |
| 1YI3 | A:38-290 | CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002 |
| 1YI4 | A:38-290 | STRUCTURE OF PIM-1 BOUND TO ADENOSINE |
| 1YWV | A:38-290 | CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA |
| 1YXS | A:38-290 | CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION |
| 1YXT | A:38-290 | CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP |
| 1YXU | D:38-290; D:38-290; D:38-290; D:38-290 | CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP |
| 1YXV | A:38-290 | CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 3,4-DIHYDROXY-1-METHYLQUINOLIN-2(1H)-ONE |
| 2O3P | A:38-290 | CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN |
| 2O65 | A:38-290 | CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE |
| 2OBJ | A:38-290 | CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR |
| 2OI4 | X:38-290 | CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE |
| 2XIX | A:38-290 | PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN |
| 2XIY | A:38-290 | PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN |
| 2XIZ | A:38-290 | PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN |
| 2XJ0 | A:38-290 | PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN |
| 2XJ1 | A:38-290 | PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR |
| 2XJ2 | A:38-290 | PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR |
| 3JPV | A:38-290 | CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[2,3-A]CARBAZOLE LIGAND |
| 3JXW | A:38-290 | DISCOVERY OF 3H-BENZO[4,5]THIENO[3,2-D]PYRIMIDIN-4-ONES AS POTENT, HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS |
| 3JY0 | A:38-290 | DISCOVERY OF 3H-BENZO[4,5]THIENO[3,2-D]PYRIMIDIN-4-ONES AS POTENT, HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS |
| 3JYA | A:38-290 | DISCOVERY OF 3H-BENZO[4,5]THIENO[3,2-D]PYRIMIDIN-4-ONES AS POTENT, HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS |
| 3MA3 | A:38-290 | CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND |
| 3QF9 | A:38-290 | CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A FURAN-THIAZOLIDINEDIONE LIGAND |
| 3R00 | A:38-290 | THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS |
| 3R01 | A:38-290 | THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS |
| 3R02 | A:38-290 | THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS |
| 3R04 | A:38-290 | THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS |
| 2OU7 | A:53-305 | STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1 |
| 2OWB | A:53-305 | STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1 |
| 2RKU | A:53-305 | STRUCTURE OF PLK1 IN COMPLEX WITH BI2536 |
| 2V5Q | B:53-305; B:53-305 | CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN |
| 2YAC | A:53-305 | CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937 |
| 3KB7 | A:53-305 | CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR |
| 3P1A | A:110-359 | STRUCTURE OF HUMAN MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE MYT1 (PKMYT1) |
| 3OWJ | A:39-324 | HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR |
| 3OWK | A:39-324 | HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR |
| 3OWL | A:39-324 | HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR |
| 3NUN | A:82-341 | PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND |
| 3NUS | A:82-341 | PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8 |
| 3NUU | A:82-341 | PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11 |
| 3NUY | A:82-341 | PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17 |
| 2V55 | C:76-338; C:76-338 | MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE |
| 3NCZ | D:76-338; D:76-338; D:76-338; D:76-338 | X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR |
| 3NDM | D:76-338; D:76-338; D:76-338; D:76-338 | CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE |
| 2JFL | A:34-292 | CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE ( DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-( AMINOSULFONYL)PHENYL)AMINO)-N-(2,6- DIFLUOROPHENYL)-1H-1,2, 4-TRIAZOLE-1-CARBOTHIOAMIDE |
| 2JFM | A:34-292 | CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM) |
| 1WAK | A:476-653; A:476-653 | X-RAY STRUCTURE OF SRPK1 |
| 2X7G | A:526-697; A:526-697 | STRUCTURE OF HUMAN SERINE-ARGININE-RICH PROTEIN-SPECIFIC KINASE 2 (SRPK2) BOUND TO PURVALANOL B |
| 3LM0 | A:33-293 | CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) |
| 3LM5 | A:33-293 | CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN |
| 2WTK | F:49-309; F:49-309; E:69-379; E:69-379 | STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX |
| 2XIK | A:20-270 | STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1) |
| 1PY5 | A:205-492 | CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR |
| 1RW8 | A:205-492 | CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR |
| 1VJY | A:205-492 | CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF-BETA TYPE I RECEPTOR |
| 2WOT | A:205-492 | ALK5 IN COMPLEX WITH 4-((5,6-DIMETHYL-2-(2-PYRIDYL)-3-PYRIDYL)OXY)-N-(3,4,5-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE |
| 2WOU | A:205-492 | ALK5 IN COMPLEX WITH 4-((4-((2,6-DIMETHYL-3-PYRIDYL)OXY)-2-PYRIDYL)AMINO)BENZENESULFONAMIDE |
| 2X7O | E:205-492; E:205-492; E:205-492; E:205-492; E:205-492 | CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR |
| 3KCF | E:205-492; E:205-492; E:205-492; E:205-492; E:205-492 | CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR |
| 1TKI | B:24-278; B:24-278 | AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN |
| 2X7F | E:25-289; E:25-289; E:25-289; E:25-289; E:25-289 | CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR |
| 2X9E | A:525-791 | HUMAN MPS1 IN COMPLEX WITH NMS-P715 |
| 2ZMC | A:525-791 | CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM |
| 2ZMD | A:525-791 | CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR |
| 2KTY | A:37-325 | SOLUTION STRUCTURE OF HUMAN VACCINIA RELATED KINASE-1 |
| 2KUL | A:37-325 | SOLUTION STRUCTURE OF HUMAN VACCINIA RELATED KINASE 1(VRK1) |
| 2LAV | A:37-325 | NMR SOLUTION STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 1 |
| 3OP5 | D:37-325; D:37-325; D:37-325; D:37-325 | HUMAN VACCINIA-RELATED KINASE 1 |
| 2V62 | B:29-312; B:29-312 | STRUCTURE OF VACCINIA-RELATED KINASE 2 |
| 2JII | B:229-452; B:229-452 | STRUCTURE OF VACCINIA RELATED KINASE 3 |
| 1X8B | A:299-569 | STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824 |
| 2Z2W | A:299-569 | HUMAN WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770 |
)
)